CommercialCoverageMedium impact
State and School Employees' Health Insurance Plan - Gene Therapy for the Treatment of Hemophilia B
Blue Cross & Blue Shield of Mississippi·MS · Hematology, Oncology·Medical Policy
We identified it
Jun 20, 2026
Summary
The State and School Employees' Health Insurance Plan has updated their policy to classify both Beqvez and Hemgenix gene therapies for Hemophilia B treatment as not medically necessary, with coverage denied due to available formulary alternatives. This affects billing for these specific gene therapy medications and their administration services.
Action Required
Immediately: Billing team must update systems to deny coverage for HCPCS codes J1411 (Hemgenix) and J1414 (Beqvez) for State and School Employees' Health Insurance Plan members. Update prior authorization systems to automatically reject these codes as not medically necessary. Inform providers that administration and delivery services related to these medications will also be denied. Direct patients to covered formulary alternatives for Hemophilia B treatment.